logo-loader

Small-Cap Snapshot: iRobot shares soar after Roomba i7 robot sales lift latest quarter

Last updated: 12:23 07 Feb 2019 EST, First published: 12:00 07 Feb 2019 EST

iRobot

Shares of iRobot Corporation (NASDAQ:IRBT) are still rallying a day after posting fiscal fourth-quarter results that beat Wall Street estimates, thanks to its Roomba i7 and i7+ robots driving holiday sales higher. In its latest reporting period, the robot maker posted a profit of $0.88 on record revenue of $385 million. The results handily zipped past the consensus forecast of $0.50 on sales of $381.26 million.

iRobot shares added 11.6% to $99.81.

Presidio (NASDAQ:PSDO) is also a top gainer after whizzing past the Street’s estimates for its fiscal second-quarter results. The IT infrastructure company posted a profit of $0.39 per share on an adjusted basis and revenue of $767.8 million. Analysts called for earnings of $0.34 per share on revenue of $682.7 million from the New York company.

Presidio stock climbed 10.4% to $16.57.

READ: EARLY MOVERS: Twitter shares flop in pre-market as 1Q guidance fails to inspire, while big bank deal boosts SunTrust Banks and BB&T Corp

Elsewhere, Sonos Inc (NASDAQ:SONO) shares are still tumbling in the wake of its CFO Michael Giannetto revealing his plans to retire. His retirement overshadowed a record fiscal first quarter where the maker of smart speakers beat the Street’s forecasts and reported earnings of $61.7 million on sales of $490.7 million. Sonos makes sophisticated wireless speakers that have developed something of a cult following.

Sonos slid 12.2% to $10.86.

Another laggard is Solid Biosciences (NASDAQ:SLDB), which is cratering on the unveiling of disappointing results from a Phase ½ trial evaluating an experimental gene therapy for the treatment of the degenerative disease Duchenne muscular dystrophy (DMD). The study evaluated three patients with this genetic disorder which is characterized by the progressive deterioration of muscles, taking the gene therapy. After three months, patients failed to report higher levels of microdystrophin, a substitute for dystrophin, the protein that these patients lack.

Solid shed 65% to hit $7.83.

Ramp Metals Launches Drilling Program in Pursuit of High-Grade Nickel in...

Ramp Metals CEO Jordan Black joined Steve Darling from Proactive to introduce the company to the public domain and share exciting developments in the mining industry. With a background as a geotechnical engineer and experience in venture capital, including a notable role in taking GoldSpot...

31 minutes ago